SEC Form 4 · accession 0001127602-18-001218
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregg H Alton
Officer — EVP Comm&Acs ALA, Corp&Med Aff
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 8:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2018 | M | 8,625 | $24.905 | A | 64,613 | D | |
| Common Stock | Jan 2, 2018 | S | 8,625 | $74.00 | D | 55,988 | D | |
| Common StockF3 | Jan 2, 2018 | S | 700 | $72.3371 | D | 55,288 | D | |
| Common StockF4 | Jan 2, 2018 | S | 5,675 | $73.8561 | D | 49,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $24.905 | Jan 2, 2018 | M | 8,625 | D | — | Jul 29, 2019 | Common Stock | 8,625 | 7,501 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $71.88 to $72.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $73.37 to $74.24. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.